Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chengmeng Wang
Institution:
Tianjin Medical University Cancer Institute and Hospital
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0002-2822-3009
Observed ORCID:
0000-0002-2822-3009
OpenAlex ID:
A5084591703
The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma
2023
·
Yuchao He
, Linlin Zhan
, et al.
·
Advanced Science
·
43
PDF
Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
2023
·
Jinfang Cui
, Yuchao He
, et al.
·
International Journal of Biological Sciences
·
35
PDF
Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT / mTOR pathway
2023
·
Chengmeng Wang
, Lu Zhang
, et al.
·
The FASEB Journal
·
19
PDF
The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
2024
·
Yu Zhang
, Chengmeng Wang
, et al.
·
Thoracic Cancer
·
5
LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues
2023
·
Zhou Fu
, Su Zhang
, et al.
·
Frontiers in Medicine
·
3
PDF
Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy
2025
·
Yuan Gao
, Yuchao He
, et al.
·
Cell Reports Medicine
·
2
[Integrative Analysis of Multi-source Public Databases to Screen Core Genes for Constructing A Prognostic Risk Model in Lung Adenocarcinoma].
2025
·
Chengmeng Wang
, Lu Zhang
, et al.
·
PubMed Central
·
1
PDF
ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis
2026
·
Zhou Fu
, Fuyi Zhu
, et al.
·
Cell Death Discovery
Adebrelimab in combination with anlotinib and chemotherapy as neoadjuvant therapy for resectable stage II-III non–small cell lung cancer (NSCLC): A prospective, single-arm, phase II trial.
2026
·
Meng Wang
, Yu Zhang
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
9
Citation count:
108
H-index:
4
I10-index:
3
Year
Topic
Type